Author

L. López

Observed institution: Complejo Asistencial Universitario de León

ORCID: 0000-0002-9286-517X

Observed ORCID: 0000-0002-9286-517X

OpenAlex ID: A5113276582

EP05.02-002 Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?

2022 · B. Tavara, M.L. Garrido, et al. · Journal of Thoracic Oncology · 1

Atezolizumab as treatment of urothelial carcinoma in second line of metastatic disease. Experience in our institution.

2023 · L. López, M.A.L. Garrido Onecha, et al. · European Urology Open Science

EP05.02-003 Durvalumab after Chemoradiotherapy (CRT) in Unresectable Stage III NSCLC. Comparative Study of Two Cohorts in the Real-World Setting

2022 · B. Tavara, M. Rojas, et al. · Journal of Thoracic Oncology

Works count: 3

Citation count: 1

H-index: 1

I10-index: